Compare Abeona Therapeutics Inc (ABEO) vs 3M Company (MMM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs 3M Company — how do they compare? Abeona Therapeutics Inc trades at $6.71 (market cap $373.32M), while 3M Company trades at $154.46 (market cap $82.41B). The key difference: 3M Company is far larger — about 220.7× Abeona Therapeutics Inc's market cap, and 3M Company pays a 1.97% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | MMM | |
|---|---|---|
Market Cap | $373.32M | $82.41B |
Sector | Health | Industrials |
52-Week High | $7.23 | $174.61 |
52-Week Low | $4.17 | $141.10 |
Enterprise Value | $228.22M | $90.82B |
Dividend Yield | — | 1.97% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
MMM trades at $158.00, down 1.52% today, with a bullish technical signal driven by moving averages. The company reported three consecutive quarterly EPS beats, with Q2 2026 results expected on July 21, 2026. Strong profitability metrics include a 72.14% ROE and 11.14% net margin, though revenue has declined from 2022 peaks. Recent news highlights partnerships with Airbus and an AI tool launch, supporting operational momentum.
Outlook is mixed: analyst consensus is a Hold with a $148.75 price target below current levels, citing limited AI exposure. Risks include volatile cash flows and high debt. Upside depends on execution of growth initiatives and margin improvement. The stock offers a dividend yield with the next payment on June 12, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About 3M Company
3M Company conducts operations in electronics, telecommunications, industrial, consumer and office, health care, safety, and other markets. The Company businesses share technologies, manufacturing operations, marketing channels, and other resources. 3M serves customers worldwide.
Read more on MMM →
